An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic (PK) Characteristics and Preliminary Efficacy of BC008-1A Injection in Subjects with Advanced Solid Tumors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs BC008 1A (Primary)
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Sichuan Luzhou Buchang Biopharmaceutical
- 20 Jan 2025 New trial record